(r)Alpha Lipoic Acid Is a Safe, Effective Pharmacologic Therapy of Chronic Orthostatic Hypotension Associated with Low Sympathetic Tone

Gary L. Murray; Joseph Colombo

doi:10.1055/s-0038-1676957

International Journal of Angiology, Table of Contents

Int J Angiol 2019; 28(03): 188-193
DOI: 10.1055/s-0038-1676957

Original Article

Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

(r)Alpha Lipoic Acid Is a Safe, Effective Pharmacologic Therapy of Chronic Orthostatic Hypotension Associated with Low Sympathetic Tone

Authors

Gary L. Murray

¹Cardiovascular Research, Heart-Vascular Institute, Germantown, Tennessee
Joseph Colombo

²Autonomic Laboratory, Drexel University College of Medicine; Parasympathetic & Sympathetic Nervous System Consultant, Franklin Cardiovascular Associates, Pennsylvania

³ANSAR Medical Technologies, Inc., Philadelphia, Pennsylvania

Abstract

Chronic orthostatic hypotension (OH), affecting 10 to 30% of the elderly, is associated with falls, and increased morbidity and mortality. Current pharmacologic therapy can cause or worsen hypertension and fluid retention. (r)α lipoic acid (ALA), a powerful natural antioxidant, avoids those complications and may assist management of chronic neurogenic orthostatic hypotension (NOH). The purpose of this study is to demonstrate improvement in the symptoms of orthostatic dysfunction with r-ALA, including improved sympathetic (S) and blood pressure (BP) responses to head-up postural change (standing).

A cohort of 109 patients with low S tone upon standing was detected using the ANX −3.0, Autonomic Monitor, ANSAR Medical Technologies, Inc., Philadelphia, PA. From the cohort, 29 patients demonstrated NOH (change in (∆) standing BP ≥ −20/–10 mm Hg); 60 patients demonstrated orthostatic intolerance (OI, ∆ standing systolic BP between –6 and –19 mm Hg). These 89 were given ALA orally: either 590 to 788 mg (r)ALA or 867 to 1,500 mg of the less expensive 50 to 50% mixture (r)ALA and inactive (s)ALA. Changes in their S and parasympathetic (P) tone, and BPs, were compared with 20 control patients during mean follow-up of 2.28 years.

Nineteen of 29 (66%) NOH patients responded with a ∆ standing BP from –28/–6 mm Hg to 0/+2 mm Hg. Forty of 60 (67%) of patients with OI responded with a ∆ standing BP of –9/+1 mm Hg to +6/+2 mm Hg. Although all patients treated with ALA increased S tone, the ∆ BP depended upon the pretreatment of S tone. Those with the lowest S tone responded the least well. The only treatment side effects were nausea, intolerable in only 5%. Nausea improved with routine gastrointestinal medications. Glucose levels improved in the 28% of patients who were diabetic. Also, resting hypertension improved. Control patients had no ∆ BP and no increase in S tone.

(r)ALA improves S-, and BP, responses to head-up postural change, and thereby NOH/OI, in a majority of patients without causing harmful side effects.

Keywords

α-lipoic acid - orthostatic hypotension - autonomic nervous system - parasympathetic nervous system - sympathetic nervous system

Full Text

References

References
1 Bradley JG, Davis KA. Orthostatic hypotension. Am Fam Physician 2003; 68 (12) 2393-2398
2 Metzler M, Duerr S, Granata R, Krismer F, Robertson D, Wenning GK. Neurogenic orthostatic hypotension: pathophysiology, evaluation, and management. J Neurol 2013; 260 (09) 2212-2219
3 Vinik AI, Maser RE, Nakave AA. Diabetic cardiovascular autonomic nerve dysfunction. US Endocrine Disease. 2007; Dec: 2–9
4 Vinik AI, Ziegler D. Diabetic cardiovascular autonomic neuropathy. Circulation 2007; 115 (03) 387-397
5 Luukinen H, Koski K, Laippala P, Kivelä SL. Prognosis of diastolic and systolic orthostatic hypotension in older persons. Arch Intern Med 1999; 159 (03) 273-280
6 Balcıoğlu AS, Müderrisoğlu H. Diabetes and cardiac autonomic neuropathy: clinical manifestations, cardiovascular consequences, diagnosis and treatment. World J Diabetes 2015; 6 (01) 80-91
7 Fleg JL, Evans GW, Margolis KL. , et al. Orthostatic hypotension in the ACCORD (Action to Control Cardiovascular Risk in Diabetes) blood pressure trial: prevalence, incidence, and prognostic significance. Hypertension 2016; 68 (04) 888-895
8 Ziegler D. Cardiovascular autonomic Neuropathy: clinical manifestations and measurement. Diabetes Rev (Alex) 1999; 7: 342-357
9 Ziegler D, Schatz H, Conrad F, Gries FA, Ulrich H, Reichel G. Effects of treatment with the antioxidant alpha-lipoic acid on cardiac autonomic neuropathy in NIDDM patients. A 4-month randomized controlled multicenter trial (DEKAN Study). Deutsche Kardiale Autonome Neuropathie. Diabetes Care 1997; 20 (03) 369-373
10 Karavaev AS, Ishbulatov YM, Ponomarenko VI. , et al. Model of human cardiovascular system with a loop of autonomic regulation of the mean arterial pressure. J Am Soc Hypertens 2016; 10 (03) 235-243
11 Ziegler D, Gries FA. Alpha-lipoic acid in the treatment of diabetic peripheral and cardiac autonomic neuropathy. Diabetes 1997; 46 (Suppl. 02) S62-S66
12 Prendergast JJ. Diabetic autonomic neuropathy: Part 2. Treatment. Practical Diabetology, June 2001; 30–36
13 Ziegler D, Ametov A, Barinov A. , et al. Oral treatment with alpha-lipoic acid improves symptomatic diabetic polyneuropathy: the SYDNEY 2 trial. Diabetes Care 2006; 29 (11) 2365-2370
14 Ametov AS, Barinov A, Dyck PJ. , et al; SYDNEY Trial Study Group. The sensory symptoms of diabetic polyneuropathy are improved with alpha-lipoic acid: the SYDNEY trial. Diabetes Care 2003; 26 (03) 770-776
15 Ziegler D, Low PA, Litchy WJ. , et al. Efficacy and safety of antioxidant treatment with α-lipoic acid over 4 years in diabetic polyneuropathy: the NATHAN 1 trial. Diabetes Care 2011; 34 (09) 2054-2060
16 Jones PK, Shaw BH, Raj SR. Orthostatic hypotension: managing a difficult problem. Expert Rev Cardiovasc Ther 2015; 13 (11) 1263-1276
17 Eschlböck S, Wenning G, Fanciulli A. Evidence-based treatment of neurogenic orthostatic hypotension and related symptoms. J Neural Transm (Vienna) 2017; 124 (12) 1567-1605
18 Gomes MB, Negrato CA. Alpha-lipoic acid as a pleiotropic compound with potential therapeutic use in diabetes and other chronic diseases. Diabetol Metab Syndr 2014; 6 (01) 80-96
19 Freeman R, Abuzinadah AR, Gibbons C, Jones P, Miglis MG, Sinn DI. Orthostatic hypotension. J Am Coll Cardiol 2018; 72 (11) 1294-1309
20 Zhang H, Jia H, Liu J. , et al. Combined R-alpha-lipoic acid and acetyl-L-carnitine exerts efficient preventative effects in a cellular model of Parkinson's disease. J Cell Mol Med 2010; 14 (1-2): 215-225
21 Biosa A, Outeiro TF, Bubacco L, Bisaglia M. Diabetes mellitus as a risk factor for Parkinson's disease: a molecular point of view. Mol Neurobiol 2018; 55 (11) 8754-8763
22 Aysin B, Colombo J, Aysin E. Comparison of HRV analysis methods during orthostatic challenge: HRV with respiration or without?. 29^th Int Conf IEEE EMBS Lyon, France, 2007
23 Akselrod S, Gordon D, Ubel FA, Shannon DC, Berger AC, Cohen RJ. Power spectrum analysis of heart rate fluctuation: a quantitative probe of beat-to-beat cardiovascular control. Science 1981; 213 (4504): 220-222
24 Akselrod S, Gordon D, Madwed JB, Snidman NC, Shannon DC, Cohen RJ. Hemodynamic regulation: investigation by spectral analysis. Am J Physiol 1985; 249 (4 Pt 2): H867-H875
25 Akselrod S, Eliash S, Oz O, Cohen S. Hemodynamic regulation in SHR: investigation by spectral analysis. Am J Physiol 1987; 253 (1 Pt 2): H176-H183
26 Akselrod S. Spectral analysis of fluctuations in cardiovascular parameters: a quantitative tool for the investigation of autonomic control. Trends Pharmacol Sci 1988; 9 (01) 6-9
27 Colombo J, Arora RR, DePace NL, Vinik AI. Clinical Autonomic Dysfunction: Measurement, Indications, Therapies, and Outcomes . New York, NY: Springer Science + Business Media; 2014
28 Lee WJ, Kim SW, Kim GH. , et al. Alpha-lipoic acid activates dimethylarginine dimethylaminohydrolase in cultured endothelial cells. Biochem Biophys Res Commun 2010; 398 (04) 653-658
29 Gouty S, Regalia J, Cai F, Helke CJ. Alpha-lipoic acid treatment prevents the diabetes-induced attenuation of the afferent limb of the baroreceptor reflex in rats. Auton Neurosci 2003; 108 (1-2): 32-44
30 Queiroz TM, Guimarães DD, Mendes-Junior LG, Braga VA. α-lipoic acid reduces hypertension and increases baroreflex sensitivity in renovascular hypertensive rats. Molecules 2012; 17 (11) 13357-13367
31 Mohammadi V, Khorvash F, Feizi A, Askari G. Does alpha-lipoic acid supplementation modulate cardiovascular risk factors in patients with stroke? A randomized, double-blind clinical trial. Int J Prev Med 2018; 9: 34
32 Tardif JC, Rhéaume E. Lipoic acid supplementation and endothelial function. Br J Pharmacol 2008; 153 (08) 1587-1588
33 Bangalore S, Messerli FH, Wun CC. , et al; Treating to New Targets Steering Committee and Investigators. J-curve revisited: an analysis of blood pressure and cardiovascular events in the Treating to New Targets (TNT) Trial. Eur Heart J 2010; 31 (23) 2897-2908
34 Mohammadi V, Dehghani S, Askari G. Does alpha-lipoic acid supplement regulate blood pressure?A systematic review of randomized, double-blind placebo-controlled clinical trials. Int J Prev Med 2017; 8: 33-38